| Species |
Human |
| Protein Construction |
| His |
CHRDL1 (Glu28-Cys456)
Accession # Q9BU40-1 |
| N-term |
C-term |
|
| Purity |
> 90% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CHRDL1, His, Human at 1μg/ml (100μl/Well) on the plate can bind AntiCHRDL1 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
50 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 50 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 4mM HCl. |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 4mM HCl. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CHRDL1 (Chordin-like 1) is a secreted protein that acts as an antagonist of bone morphogenetic protein (BMP). BMP plays a role as an activator of BMP receptor II (BMPR II), which mediates extracellular to intracellular signal transmission and is involved in carcinogenesis and metastasis.The hypermethylation of the CHRDL1 promoter in gastric cancer, which induced low expression of CHRDL1 and decreased its secretion to the supernatant. |
| Synonyms |
Neuralin-1; Neurogenesin-1; Ventroptin; CHRDL1; NRLN1; CHL; Chordin-like 1; CRDL1; dA141H5.1; VOPT |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
